A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Bioseeker, April 2011, Pages: 1147

This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia. BioSeeker has applied its unique drug assessment methodology to stratify the leukemia pipeline and discern the level of competition in fine detail.

Major Findings from this report:

- The identified competitive landscape of leukemia drugs is split between the 49% which have unique drug target strategies and the other part which have head-to-head target competing leukemia drugs in 41 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the leukemia drugs in general. Contributing to this fact is heavily utilized drug target strategies like: IFNAR2, TOP2A, MS4A1 and CD33.

- Eight out of ten drug target strategies in Phase II development are new to leukemia drugs and at the same time the greatest numbers of new target strategies are found in Phase II (34%) and Phase I development (19%).

- Small molecules, antibodies and proteins are the dominating compound strategies of leukemia drugs, which represent almost 90% of the entire pipeline. Cell therapy based leukemia drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of leukemia drugs.

- The highest number of described drug target strategies of leukemia drugs belongs to Novartis (9), Pfizer (9) and Bristol-Myers Squibb (8).

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

- Supporting development of integrative molecule, pathway and disease area strategies

- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any leukemia drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary
2 About Cancer Highlights™
2.1 Cancer Focus Areas
2.2 Subscribe Today and Start Saving
2.2.1 Type of License
2.3 BioSeeker Group’s Oncology Team
3 Methodology
3.1 Cancer Highlights’™ Five Pillar Drug Assessment
4

4.1 List of Figures
4.2 List of Tables
5 Introduction
5.1 The Scope of this Report
5.2 Definitions
5.3 Abbreviations
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment
6.1 Drug Repositioning in Oncology
6.2 Introduction to Targets of Leukemia Drugs
6.2.1 Antigen Binding Targets
6.2.2 Carboxy-lyase Activity Targets
6.2.3 Catalytic Activity Targets
6.2.4 Cell Adhesion Molecule Activity Targets
6.2.5 Chaperone Activity Targets
6.2.6 Chemokine Activity Targets
6.2.7 Cysteine-type Peptidase Activity Targets
6.2.8 Cytokine Activity Targets
6.2.9 Deaminase Activity Targets
6.2.10 Defense/Immunity Protein Activity Targets
6.2.11 DNA Binding Targets
6.2.12 DNA Repair Protein Targets
6.2.13 DNA Topoisomerase Activity Targets
6.2.14 DNA-directed DNA Polymerase Activity Targets
6.2.15 DNA-methyltransferase Activity Targets
6.2.16 G-protein Coupled Receptor Activity Targets
6.2.17 Growth Factor Activity Targets
6.2.18 GTPase Activator Activity Targets
6.2.19 Hydrolase Activity Targets
6.2.20 Kinase Activity Targets
6.2.21 Kinase Binding Targets
6.2.22 Kinase Regulator Activity Targets
6.2.23 Ligand-dependent Nuclear Receptor Activity Targets
6.2.24 Ligase Activity Targets
6.2.25 Lipid Kinase Activity Targets
6.2.26 Lipid Phosphatase Activity Targets
6.2.27 Methyltransferase Activity Targets
6.2.28 MHC Class I Receptor Activity Targets
6.2.29 Molecular Function Unknown Targets
6.2.30 Motor Activity Targets
6.2.31 Oxidoreductase Activity Targets
6.2.32 Phosphoric Diester Hydrolase Activity Targets
6.2.33 Phosphorylase Activity Targets
6.2.34 Protein Binding Targets
6.2.35 Protein Serine/Threonine Kinase Activity Targets
6.2.36 Protein Threonine/Tyrosine Kinase Activity Targets
6.2.37 Protein Tyrosine Phosphatase Activity Targets
6.2.38 Protein-tyrosine Kinase Activity Targets
6.2.39 Receptor Activity Targets
6.2.40 Receptor Binding Targets
6.2.41 Receptor Signaling Complex Scaffold Activity Targets
6.2.42 RNA Binding Targets
6.2.43 RNA-directed DNA Polymerase Activity Targets
6.2.44 Serine-type Peptidase Activity Targets
6.2.45 Structural Constituent of Cytoskeleton Targets
6.2.46 Superoxide Dismutase Activity Targets
6.2.47 T Cell Receptor Activity Targets
6.2.48 Transcription Factor Activity Targets
6.2.49 Transcription Regulator Activity Targets
6.2.50 Transferase Activity Targets
6.2.51 Translation Regulator Activity Targets
6.2.52 Transmembrane Receptor Activity Targets
6.2.53 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.2.54 Transporter Activity Targets
6.2.55 Ubiquitin-specific Protease Activity Targets
6.2.56 Other Targets
6.3 The Cancer Genome Project and Targets of Leukemia Drugs
6.3.1 Targets of Leukemia Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.4 Structure-based Drug Design in Leukemia Therapeutics is Stimulated by Available Structure Data on Biological Targets
6.5 Target-Target Interactions among Identified Targets of Leukemia Drugs
6.6 The Drug-Target Competitive Landscape
6.7 Protein Expression Levels of Identified Targets of Leukemia Drugs
6.8 Pathway Assessment of Leukemia Drugs
6.8.1 Tools for Analysis of Cancer Pathways
6.8.2 Pathway Assessment
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Leukemia Drugs
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Leukemia Drugs
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Leukemia Drugs
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Leukemia Drugs
7.5 Preclinical Development: New and Unique Drug Target Strategies of Leukemia Drugs
7.6 Drug Target Strategies of Suspended or Terminated Leukemia Drugs
7.7 Target Strategy Development Profiles of Leukemia Drugs
7.7.1 Marketed
7.7.2 Pre-registration
7.7.3 Phase III
7.7.4 Phase II
7.7.5 Phase I
7.7.6 Preclinical
7.7.7 Ceased
7.8 The Competition Through Close Mechanistic Approximation of Leukemia Drugs
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy
8.1 Small Molecules
8.1.1 Background
8.1.2 Target Strategies of Small Molecule Drugs
8.2 Peptide & Protein Drugs
8.2.1 Background
8.2.2 Target Strategies of Peptide and Protein Drugs
8.3 Antibodies and Antibody-like Structures
8.3.1 Background
8.3.2 Target Strategies of Antibody Drugs
8.4 Nucleic Acid Therapies
8.4.1 Background
8.4.2 Target Strategies of Nucleic Acid Drugs
8.5 Cell & Gene Therapy
8.5.1 Background
8.5.2 Target Strategies of Cell and Gene Therapy Drugs
8.6 Drug Delivery and Nanotechnology
8.6.1 Background
8.6.2 Target Strategies of Reformulated Drugs
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets
9 Selecting Subindication for Leukemia Drugs
9.1 Acute Lymphocytic Leukemia
9.2 Acute Myelogenous Leukemia
9.3 Chronic Lymphocytic Leukemia
9.4 Chronic Myelogenous Leukemia
9.5 Chronic Myelomonocytic Leukemia
9.6 Hairy Cell Leukemia
9.7 Mast Cell Leukemia
9.8 Leukemia (general)
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator
10.1 Competitive Fall-Out Assessment
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
10.3 3M Pharmaceuticals
10.4 4SC
10.5 Abbott
10.6 Abiogen
10.7 Actinium Pharmaceuticals
10.8 Advaxis
10.9 AEgera
10.10 Agenus
10.11 Alexion
10.12 Alfa Wassermann
10.13 Altor BioScience
10.14 Ambit Biosciences
10.15 Amgen
10.16 Antisoma
10.17 Arca biopharma
10.18 Ariad
10.19 Arno Therapeutics
10.20 Array BioPharma
10.21 Asahi Kasei Pharma
10.22 Ascenta Therapeutics
10.23 Astellas
10.24 Astex Therapeutics
10.25 AstraZeneca
10.26 Attenuon
10.27 Bayer
10.28 Bio-Path Holdings
10.29 BioCryst Pharmaceuticals
10.30 Bioenvision
10.31 Biogen Idec
10.32 BioSante
10.33 Bioton
10.34 Boehringer Ingelheim
10.35 Bristol-Myers Squibb
10.36 BTG
10.37 Callisto Pharmaceuticals
10.38 Celator Pharmaceuticals
10.39 Celera
10.40 Celgene
10.41 Cell Therapeutics
10.42 Celldex Therapeutics
10.43 Cephalon
10.44 Choongwae
10.45 CJ Corp
10.46 Clavis Pharma
10.47 Cornerstone Pharmaceuticals
10.48 CSL
10.49 Curacyte
10.50 CureTech
10.51 Cyclacel
10.52 Cylene Pharmaceuticals
10.53 CytImmune Sciences
10.54 Cytokinetics
10.55 Daiichi Sankyo
10.56 Dainippon Sumitomo Pharma
10.57 Dara Biosciences
Deciphera Pharmaceuticals
10.58 DiaMedica
10.59 Dong-A
10.60 Eleos
10.61
10.62 Eli Lilly
10.63 Emergent BioSolutions
10.64 EntreMed
10.65 Enzon
10.66 EpiCept
10.67 Epizyme
10.68 Erimos
10.69 Esperance Pharmaceuticals
10.70 Exelixis
10.71 ExonHit Therapeutics
10.72 Gemin X Biotechnologies
10.73 Genencor
10.74 Genentech
10.75 Genmab
10.76 Genta
10.77 Genzyme
10.78 Geron
10.79 Gilead Sciences
10.80 GlaxoSmithKline
10.81 GlycoGenesys
10.82 GlycoMimetics
10.83 Hanmi
10.84 Hayashibara
10.85 Heber Biotec
10.86 Hoffmann-La Roche
10.87 IDM Pharma
10.88 IkerChem
10.89 ImClone Systems
10.90 Immune Pharmaceuticals
10.91 Immunocore
10.92 ImmunoGen
10.93 Immunomedics
10.94 Incyte Corporation
10.95 InDex Pharmaceuticals
10.96 Inex
10.97 Innate Pharma
10.98 Innovive
10.99 Insys Therapeutics
10.100 Intas Biopharmaceuticals
10.101 Isis Pharmaceuticals
10.102 Italfarmaco
10.103 Johnson & Johnson
10.104 KaloBios
10.105 Kanisa
10.106 Kinex
10.107 Kyowa Hakko Kirin
10.108 Leo
10.109 LFB Biotechnologies
10.110 LG Life Sciences
10.111 Ligand
10.112 Lorus Therapeutics
10.113 MAT Biopharma
10.114 MaxCyte
10.115 MaxoCore Pharmaceuticals
10.116 Meda
10.117 MediGene
10.118 Memgen
10.119 Merck & Co
10.120 Merck KGaA
10.121 MethylGene
10.122 Micromet
10.123 Mologen
10.124 Nereus Pharmaceuticals
10.125 Nerviano Medical Sciences
10.126 NIH – The US National Institute of Health
10.127 Nippon Shinyaku
10.128 Non-industrial source
10.129 Novartis
10.130 Novogen
10.131 Onconova
10.132 OSI Pharmaceuticals
10.133 Otsuka
10.134 Pfizer
10.135 Pharmacyclics
10.136 PharmaMar
10.137 PIERIS Proteolab
10.138 Pierre Fabre
10.139 Piramal
10.140 Portola Pharmaceuticals
10.141 Prochon Biotech
10.142 ProMetic Life Sciences
10.143 Reata Pharmaceuticals
10.144 Reliance Life Sciences
10.145 Rigel
10.146 Sangamo BioSciences
10.147 Sanofi-Aventis
10.148 Santaris Pharma
10.149 Sareum
10.150 SBI Biotech
10.151 SBIO
10.152 Seattle Genetics
10.153 Semafore Pharmaceuticals
10.154 Sepal Pharma
10.155 Servier
10.156 Shenogen
10.157 Shire
10.158 Sidus
10.159 Southern Research Institute
10.160 Spirogen
10.161 Stemline Therapeutics
10.162 SuperGen
10.163 Swedish Orphan Biovitrum
10.164 SymBio Pharmaceuticals
10.165 Symbiotec
10.166 Synageva BioPharma
10.167 Synta Pharmaceuticals
10.168 Syntrix
10.169
10.170 Takeda
10.171 Talon Therapeutics
10.172 Targa Therapeutics
10.173 TargeGen
10.174 TeGenero
10.175 Teva
10.176 TopoTarget
10.177 Trion Pharma
10.178 Valeant
10.179 Vertex Pharmaceuticals
10.180 Vion Pharmaceuticals
10.181 VioQuest Pharmaceuticals
10.182 XBiotech
10.183 Xencor
10.184 Yamasa Corporation
10.185 Zenyaku Kogyo
11 Disclaimer
12 Drug Index
13 Company Index

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Leukemia Drugs
Figure 2: The Drug-Target Competitive Landscape of Leukemia Drugs - Large Cluster
Figure 3: The Drug-Target Competitive Landscape Leukemia Drugs - Smaller Clusters
Figure 4: Head-to-Head Targeting Competitive Landscape of Leukemia Drugs
Figure 5: Distribution of Compound Strategies among Leukemia Drugs
Figure 6: Primary Sub-cellular Localization of Drug Targets

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment
Table 2: Breakdown of the Included Leukemia Drug Pipeline by Stage of Development
Table 3: Head to Head Target Competition among Leukemia Drugs
Table 4: Overview of Drug Target Strategy Themes
Table 5: Terminally Ceased Targets of Leukemia Drugs
Table 6: Official Gene Name to Target Profle
Table 7: Targets of Leukemia Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 8: Identity of Leukemia Drug Targets with Available Biological Structures
Table 9: Number of Target-Target Interactions among Targets of Leukemia Drugs
Table 10: Available Protein Expression Profiles of Leukemia Drugs Targets
Table 11: Pathway Summary
Table 12: Drug Targets without any Identified Assigned Pathways
Table 13: Pathway Profiles According to BioCarta of Leukemia Drug Targets
Table 14: Pathway Profiles According to KEGG of Leukemia Drug Targets
Table 15: Pathway Profiles According to NetPath of Leukemia Drug Targets
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness
Table 17: Top Competitive Target Strategies of Leukemia Drugs
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Leukemia Drugs
Table 19: The Competition Through Close Mechanistic Approximation Between Leukemia Drugs being Marketed or in Pre-registration
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Leukemia Drugs
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Leukemia Drugs
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Leukemia Drugs
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Leukemia Drugs
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Leukemia Drugs
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Leukemia Drugs
Table 26: New and Unique Target Strategies in Preclinical Development of Leukemia Drugs
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Leukemia Drugs
Table 28: Target Strategies of Suspended and Terminated Leukemia Drugs
Table 29: Connecting Target Strategy with Its Profile Identification Number
Table 30: The Competition Through Close Mechanistic Approximation Among Leukemia Drugs
Table 31: Overview of Compound Strategy Competition Among Leukemia Drugs
Table 32: Overview of the Competitive Landscape of Small Molecule Based Leukemia Drugs
Table 33: Competitive Comparison of Target Strategies of Small Molecule Leukemia Drugs
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Leukemia Drugs
Table 35: Overview of the Competitive Landscape of Peptide Based Leukemia Drugs
Table 36: Pursued Target Strategies of Peptide Based Leukemia Drugs
Table 37: Overview of the Competitive Landscape of Protein Based Leukemia Drugs
Table 38: Competitive Comparison of Target Strategies of Protein Based Leukemia Drugs
Table 39: Pursued Target Strategies of Protein Based Leukemia Drugs
Table 40: Overview of the Competitive Landscape of Antibody Based Leukemia Drugs
Table 41: Competitive Comparison of Target Strategies of Antibody Based Leukemia Drugs
Table 42: Pursued Target Strategies of Antibody Based Leukemia Drugs
Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Leukemia Drugs
Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Leukemia Drugs
Table 45: Pursued Target Strategies of Nucleic Acid Based Leukemia Drugs
Table 46: Potential Forms of Cell Therapy
Table 47: Vectors in Gene Therapy
Table 48: Overview of the Competitive Landscape of Cell Therapy Based Leukemia Drugs
Table 49: Pursued Target Strategies of Cell Therapy Based Leukemia Drugs
Table 50: Overview of the Competitive Landscape of Gene Therapy Based Leukemia Drugs
Table 51: Pursued Target Strategies of Gene Therapy Based Leukemia Drugs
Table 52:Overview of the Competitive Landscape of Reformulated Leukemia Drugs
Table 53: Pursued Target Strategies of Reformulated Leukemia Drugs
Table 54: Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets
Table 55 Competitive Summary by Subindication of Leukemia Drugs
Table 56: Target Strategy Development Profiles of Drugs for the Treatment of Acute Lymphocytic Leukemia
Table 57: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs
Table 58: Target Strategy Development Profiles of Drugs for the Treatment of Acute Myelogenous Leukemia
Table 59: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia
Table 60: Target Strategy Development Profiles of Drugs for the Treatment of Chronic Lymphocytic Leukemia
Table 61: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs
Table 62: Target Strategy Development Profiles of Drugs for the Treatment of Chronic Myelogenous Leukemia
Table 63: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs
Table 64: Target Strategy Development Profiles of Drugs for the Treatment of Chronic Myelomonocytic Leukemia
Table 65: Target Strategy Development Profiles of Drugs for the Treatment of Hairy Cell Leukemia
Table 66: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs
Table 67: Target Strategy Development Profiles of Drugs for the Treatment of Mast Cell Leukemia
Table 68: Target Strategy Development Profiles of Drugs for the Treatment of Leukemia (general)
Table 69: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs
Table 70: Example of a Competitive Fall-Out Table (Targeting TOP2A)
Table 71: Summary Table of Corporate Changes in the Competitive Landscape of Leukemia Drug Development
Table 72: 3M Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 73: 4SC's Included Leukemia Pipeline and Competitive Fall-Out
Table 74: Abbott's Included Leukemia Pipeline and Competitive Fall-Out
Table 75: Abiogen's Included Leukemia Pipeline and Competitive Fall-Out
Table 76: Actinium Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 77: Advaxis’ Included Leukemia Pipeline and Competitive Fall-Out
Table 78: AEgera's Included Leukemia Pipeline and Competitive Fall-Out
Table 79: Agenus’ Included Leukemia Pipeline and Competitive Fall-Out
Table 80: Alexion's Included Leukemia Pipeline and Competitive Fall-Out
Table 81: Alfa Wassermann's Included Leukemia Pipeline and Competitive Fall-Out
Table 82: Altor BioScience's Included Leukemia Pipeline and Competitive Fall-Out
Table 83: Ambit Biosciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 84: Amgen's Included Leukemia Pipeline and Competitive Fall-Out
Table 85: Antisoma's Included Leukemia Pipeline and Competitive Fall-Out
Table 86: Arca biopharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 87: Ariad's Included Leukemia Pipeline and Competitive Fall-Out
Table 88: Arno Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 89: Array BioPharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 90: Asahi Kasei Pharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 91: Ascenta Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 92: Astellas’ Included Leukemia Pipeline and Competitive Fall-Out
Table 93: Astex Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 94: AstraZeneca's Included Leukemia Pipeline and Competitive Fall-Out
Table 95: Attenuon's Included Leukemia Pipeline and Competitive Fall-Out
Table 96: Bayer's Included Leukemia Pipeline and Competitive Fall-Out
Table 97: Bio-Path Holdings’ Included Leukemia Pipeline and Competitive Fall-Out
Table 98: BioCryst Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 99: Bioenvision's Included Leukemia Pipeline and Competitive Fall-Out
Table 100: Biogen Idec's Included Leukemia Pipeline and Competitive Fall-Out
Table 101: BioSante's Included Leukemia Pipeline and Competitive Fall-Out
Table 102: Bioton's Included Leukemia Pipeline and Competitive Fall-Out
Table 103: Boehringer Ingelheim's Included Leukemia Pipeline and Competitive Fall-Out
Table 104: Bristol-Myers Squibb's Included Leukemia Pipeline and Competitive Fall-Out
Table 105: BTG's Included Leukemia Pipeline and Competitive Fall-Out
Table 106: Callisto Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 107: Celator Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 108: Celera's Included Leukemia Pipeline and Competitive Fall-Out
Table 109: Celgene's Included Leukemia Pipeline and Competitive Fall-Out
Table 110: Cell Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 111: Celldex Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 112: Cephalon's Included Leukemia Pipeline and Competitive Fall-Out
Table 113: Choongwae's Included Leukemia Pipeline and Competitive Fall-Out
Table 114: CJ Corp's Included Leukemia Pipeline and Competitive Fall-Out
Table 115: Clavis Pharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 116: Cornerstone Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 117: CSL's Included Leukemia Pipeline and Competitive Fall-Out
Table 118: Curacyte's Included Leukemia Pipeline and Competitive Fall-Out
Table 119: CureTech's Included Leukemia Pipeline and Competitive Fall-Out
Table 120: Cyclacel's Included Leukemia Pipeline and Competitive Fall-Out
Table 121: Cylene Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 122: CytImmune Sciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 123: Cytokinetics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 124: Daiichi Sankyo's Included Leukemia Pipeline and Competitive Fall-Out
Table 125: Dainippon Sumitomo Pharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 126: Dara Biosciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 127: Deciphera Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 128: DiaMedica's Included Leukemia Pipeline and Competitive Fall-Out
Table 129: Dong-A's Included Leukemia Pipeline and Competitive Fall-Out
Table 130: Eleos’ Included Leukemia Pipeline and Competitive Fall-Out
Table 131: Eli Lilly's Included Leukemia Pipeline and Competitive Fall-Out
Table 132: Emergent BioSolutions’ Included Leukemia Pipeline and Competitive Fall-Out
Table 133: EntreMed's Included Leukemia Pipeline and Competitive Fall-Out
Table 134: Enzon's Included Leukemia Pipeline and Competitive Fall-Out
Table 135: EpiCept's Included Leukemia Pipeline and Competitive Fall-Out
Table 136: Epizyme's Included Leukemia Pipeline and Competitive Fall-Out
Table 137: Erimos’ Included Leukemia Pipeline and Competitive Fall-Out
Table 138: Esperance Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 139: Exelixis’ Included Leukemia Pipeline and Competitive Fall-Out
Table 140: ExonHit Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 141: Gemin X Biotechnologies’ Included Leukemia Pipeline and Competitive Fall-Out
Table 142: Genencor's Included Leukemia Pipeline and Competitive Fall-Out
Table 143: Genentech's Included Leukemia Pipeline and Competitive Fall-Out
Table 144: Genmab's Included Leukemia Pipeline and Competitive Fall-Out
Table 145: Genta's Included Leukemia Pipeline and Competitive Fall-Out
Table 146: Genzyme's Included Leukemia Pipeline and Competitive Fall-Out
Table 147: Geron's Included Leukemia Pipeline and Competitive Fall-Out
Table 148: Gilead Sciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 149: GlaxoSmithKline's Included Leukemia Pipeline and Competitive Fall-Out
Table 150: GlycoGenesys’ Included Leukemia Pipeline and Competitive Fall-Out
Table 151: GlycoMimetics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 152: Hanmi's Included Leukemia Pipeline and Competitive Fall-Out
Table 153: Hayashibara's Included Leukemia Pipeline and Competitive Fall-Out
Table 154: Heber Biotec's Included Leukemia Pipeline and Competitive Fall-Out
Table 155: Hoffmann-La Roche's Included Leukemia Pipeline and Competitive Fall-Out
Table 156: IDM Pharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 157: IkerChem's Included Leukemia Pipeline and Competitive Fall-Out
Table 158: ImClone Systems’ Included Leukemia Pipeline and Competitive Fall-Out
Table 159: Immune Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 160: Immunocore's Included Leukemia Pipeline and Competitive Fall-Out
Table 161: ImmunoGen's Included Leukemia Pipeline and Competitive Fall-Out
Table 162: Immunomedics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 163: Incyte Corporation's Included Leukemia Pipeline and Competitive Fall-Out
Table 164: InDex Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 165: Inex's Included Leukemia Pipeline and Competitive Fall-Out
Table 166: Innate Pharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 167: Innovive's Included Leukemia Pipeline and Competitive Fall-Out
Table 168: Insys Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 169: Intas Biopharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 170: Isis Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 171: Italfarmaco's Included Leukemia Pipeline and Competitive Fall-Out
Table 172: Johnson & Johnson's Included Leukemia Pipeline and Competitive Fall-Out
Table 173: KaloBios’ Included Leukemia Pipeline and Competitive Fall-Out
Table 174: Kanisa's Included Leukemia Pipeline and Competitive Fall-Out
Table 175: Kinex's Included Leukemia Pipeline and Competitive Fall-Out
Table 176: Kyowa Hakko Kirin's Included Leukemia Pipeline and Competitive Fall-Out
Table 177: Leo's Included Leukemia Pipeline and Competitive Fall-Out
Table 178: LFB Biotechnologies’ Included Leukemia Pipeline and Competitive Fall-Out
Table 179: LG Life Sciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 180: Ligand's Included Leukemia Pipeline and Competitive Fall-Out
Table 181: Lorus Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 182: MAT Biopharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 183: MaxCyte's Included Leukemia Pipeline and Competitive Fall-Out
Table 184: MaxoCore Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 185: Meda's Included Leukemia Pipeline and Competitive Fall-Out
Table 186: MediGene's Included Leukemia Pipeline and Competitive Fall-Out
Table 187: Memgen's Included Leukemia Pipeline and Competitive Fall-Out
Table 188: Merck & Co's Included Leukemia Pipeline and Competitive Fall-Out
Table 189: Merck KGaA's Included Leukemia Pipeline and Competitive Fall-Out
Table 190: MethylGene's Included Leukemia Pipeline and Competitive Fall-Out
Table 191: Micromet's Included Leukemia Pipeline and Competitive Fall-Out
Table 192: Mologen's Included Leukemia Pipeline and Competitive Fall-Out
Table 193: Nereus Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 194: Nerviano Medical Sciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 195: NIH's Included Leukemia Pipeline and Competitive Fall-Out
Table 196: Nippon Shinyaku's Included Leukemia Pipeline and Competitive Fall-Out
Table 197: Non-industrial source's Included Leukemia Pipeline and Competitive Fall-Out
Table 198: Novartis’ Included Leukemia Pipeline and Competitive Fall-Out
Table 199: Novogen's Included Leukemia Pipeline and Competitive Fall-Out
Table 200: Onconova's Included Leukemia Pipeline and Competitive Fall-Out
Table 201: OSI Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 202: Otsuka's Included Leukemia Pipeline and Competitive Fall-Out
Table 203: Pfizer's Included Leukemia Pipeline and Competitive Fall-Out
Table 204: Pharmacyclics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 205: PharmaMar's Included Leukemia Pipeline and Competitive Fall-Out
Table 206: PIERIS Proteolab's Included Leukemia Pipeline and Competitive Fall-Out
Table 207: Pierre Fabre's Included Leukemia Pipeline and Competitive Fall-Out
Table 208: Piramal's Included Leukemia Pipeline and Competitive Fall-Out
Table 209: Portola Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 210: Prochon Biotech's Included Leukemia Pipeline and Competitive Fall-Out
Table 211: ProMetic Life Sciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 212: Reata Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 213: Reliance Life Sciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 214: Rigel's Included Leukemia Pipeline and Competitive Fall-Out
Table 215: Sangamo BioSciences’ Included Leukemia Pipeline and Competitive Fall-Out
Table 216: Sanofi-Aventis’ Included Leukemia Pipeline and Competitive Fall-Out
Table 217: Santaris Pharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 218: Sareum's Included Leukemia Pipeline and Competitive Fall-Out
Table 219: SBI Biotech's Included Leukemia Pipeline and Competitive Fall-Out
Table 220: SBIO's Included Leukemia Pipeline and Competitive Fall-Out
Table 221: Seattle Genetics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 222: Semafore Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 223: Sepal Pharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 224: Servier's Included Leukemia Pipeline and Competitive Fall-Out
Table 225: Shenogen's Included Leukemia Pipeline and Competitive Fall-Out
Table 226: Shire's Included Leukemia Pipeline and Competitive Fall-Out
Table 227: Sidus’ Included Leukemia Pipeline and Competitive Fall-Out
Table 228: Southern Research Institute's Included Leukemia Pipeline and Competitive Fall-Out
Table 229: Spirogen's Included Leukemia Pipeline and Competitive Fall-Out
Table 230: Stemline Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 231: SuperGen's Included Leukemia Pipeline and Competitive Fall-Out
Table 232: Swedish Orphan Biovitrum's Included Leukemia Pipeline and Competitive Fall-Out
Table 233: SymBio Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 234: Symbiotec's Included Leukemia Pipeline and Competitive Fall-Out
Table 235: Synageva BioPharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 236: Synta Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 237: Syntrix's Included Leukemia Pipeline and Competitive Fall-Out
Table 238: Takeda's Included Leukemia Pipeline and Competitive Fall-Out
Table 239: Talon Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 240: Targa Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out
Table 241: TargeGen's Included Leukemia Pipeline and Competitive Fall-Out
Table 242: TeGenero's Included Leukemia Pipeline and Competitive Fall-Out
Table 243: Teva's Included Leukemia Pipeline and Competitive Fall-Out
Table 244: TopoTarget's Included Leukemia Pipeline and Competitive Fall-Out
Table 245: Trion Pharma's Included Leukemia Pipeline and Competitive Fall-Out
Table 246: Valeant's Included Leukemia Pipeline and Competitive Fall-Out
Table 247: Vertex Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 248: Vion Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 249: VioQuest Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out
Table 250: XBiotech's Included Leukemia Pipeline and Competitive Fall-Out
Table 251: Xencor's Included Leukemia Pipeline and Competitive Fall-Out
Table 252: Yamasa Corporation's Included Leukemia Pipeline and Competitive Fall-Out
Table 253: Zenyaku Kogyo's Included Leukemia Pipeline and Competitive Fall-Out

Customers who bought this item also bought

• Leukemia Therapeutics Market (2010-2020) (Acute/Chronic lymphocytic leukemia & Acute/Chronic myeloid leukemia) Pipeline forecast & Market forecast in G8 countries
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2013
• Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2013
• Leukemia Partnering 2007-2013
• Global Hematologic Disorders Drug Pipeline Capsule – 2012
• Global Chronic Myeloid Leukemia Drug Pipeline Capsule - 2011
• Global Chronic Myeloid Leukemia Drug Pipeline Capsule - 2012 Update